|By PR Newswire||
|April 7, 2014 08:30 AM EDT||
HOUSTON, April 7, 2014 /PRNewswire/ -- C4 Imaging LLC is pleased to announce the first patient implant with Sirius™, its novel positive-signal MRI Marker. Sirius™ is used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure. The first implant was performed at The University of Texas MD Anderson Cancer Center (Houston, Texas) and was used during a procedure with IsoRay™ Medical's Cesium-131 seeds.
"This first implant is a significant milestone," said Andrew Bright, President and CEO of C4 Imaging. "MR imaging of the implanted Sirius™ MRI Markers was successful and the clinical team were able to localize the implanted seeds." He added, "We were delighted to partner with IsoRay™ Medical for this first implant. IsoRay are leading innovators in the use of brachytherapy to treat prostate cancer, as well as many other tumors, and recognize the potential of MR imaging to optimize treatment quality and patient care."
IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen to partner with C4 Imaging's innovative positive-signal MRI Markers in the treatment of prostate cancer. This combines two of the newest technologies available in brachytherapy with the goal of improving patient outcomes."
Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 radioactive seeds into the prostate. Its popularity has increased due to its effectiveness, convenience, relatively low incidence of erectile dysfunction, and minimal invasiveness . Radiation released from the seeds penetrates the surrounding prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy can be excellent but depend greatly on the quality of the implant: 8-year prostate-specific antigen (PSA) relapse-free survival rates of 93% for high-quality implants vs. 76% for low-quality ones have been reported .
About C4 IMAGING
C4 Imaging LLC develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company's core proprietary technology, C4, has been developed as Sirius™ the first commercially available Positive-Signal MRI Marker. Further information is available at www.c4imaging.com
For further information please contact:
President and CEO
Tel: 609 933 5895
Copyright © 2014
Sirius is a trademark of C4 Imaging.
IsoRay is a trademark of IsoRay Medical.
- Frank SJ, et al. American College of Radiology Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer. Brachytherapy. 2011; 10(5): 357-362.
- Zelefsky MJ, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67(2): 327-333.
SOURCE C4 Imaging
Sep. 29, 2016 01:00 AM EDT Reads: 2,298
Sep. 29, 2016 12:15 AM EDT Reads: 482
Sep. 29, 2016 12:00 AM EDT Reads: 2,929
Sep. 28, 2016 11:30 PM EDT Reads: 2,727
Sep. 28, 2016 11:30 PM EDT Reads: 3,952
Sep. 28, 2016 10:30 PM EDT Reads: 3,061
Sep. 28, 2016 09:15 PM EDT Reads: 353
Sep. 28, 2016 08:30 PM EDT Reads: 1,715
Sep. 28, 2016 08:15 PM EDT Reads: 343
Sep. 28, 2016 07:00 PM EDT Reads: 1,627
Sep. 28, 2016 06:45 PM EDT Reads: 4,153
Sep. 28, 2016 06:30 PM EDT Reads: 3,119
Sep. 28, 2016 06:15 PM EDT Reads: 305
Sep. 28, 2016 06:00 PM EDT Reads: 1,777
Sep. 28, 2016 05:15 PM EDT Reads: 261